...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmaceutical patent analyst >Novel platinum compounds and nanoparticles as anticancer agents
【24h】

Novel platinum compounds and nanoparticles as anticancer agents

机译：新型铂化合物和纳米粒子作为抗癌剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Since the approval of cisplatin in 1979, platinum-based drugs have been regulariy used in cancer chemotherapy as a first-line treatment or with the combination of other nonpiatinum drugs. Subsequent approval of second- and third-generation drugs such as carboplatin and oxaliplatin respectively, has widened the therapeutic achievement of piatinum compounds. There are few other platinum drugs approved recently and many other new drugs as well as the formulations of the old ones are going through clinical trials now. Considering the astonishing achievement of these drugs, analyses on the overall scenario of the patent applications on platinum compounds have become the priority to the scientific community. This review summarizes the published patent applications on the novel platinum anticancer compounds from 2012 to 2017 (August).
机译：自1979年的顺铂批准以来，铂族的药物已经在癌症化疗中使用作为一线治疗或其他非百分子药物的组合。 随后分别批准了诸如卡巴铂和奥沙利铂等第二代药物的批准，扩大了紫杉醇化合物的治疗成就。 最近还有很少批准的铂毒品，以及许多其他新药以及旧药物的配方现在正在经历临床试验。 考虑到这些药物的令人惊讶的成就，对铂化合物的专利申请的总体情况分析已成为科学界的优先权。 本综述总结了2012年至2017年新型铂抗癌化合物上已发表的专利申请（8月）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号